Dana Steen
Family · Chesterfield, SCNPI 1407487689
Payments from drug & device makers
Across 101 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$733
- Novo Nordisk$235
- Amgen$149
- Boehringer Ingelheim$148
- Lilly USA, LLC$102
- Novartis$68
- plus $484 from 16 others
What the payments were for
- Food & beverage$1,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $733 |
| Novo Nordisk | 15 | $235 |
| Amgen | 9 | $149 |
| Boehringer Ingelheim | 10 | $148 |
| Lilly USA, LLC | 7 | $102 |
| Novartis | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Dexcom, Inc. | 2 | $46 |
| Corcept Therapeutics | 2 | $40 |
| AstraZeneca | 2 | $38 |
| Aytu Biopharma, Inc. | 3 | $37 |
| Stryker | 1 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Pfizer | 2 | $28 |
| Alkermes, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Merck | 2 | $25 |
| Exact Sciences | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $14 |
How this compares
$1,919 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $78,966 |
| JardianceEmpagliflozin | 59 | $76,399 |
| TrulicityDulaglutide | 52 | $63,259 |
| OzempicSemaglutide | 31 | $36,214 |
| VraylarCariprazine Hcl | 22 | $29,794 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $21,911 |
| EntrestoSacubitril/Valsartan | 21 | $17,947 |
| XareltoRivaroxaban | 13 | $16,349 |
| Repatha SyringeEvolocumab | 15 | $10,891 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,497 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $2,937 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,825 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 11 | $2,129 |
| Gabapentin | 162 | $1,762 |
| Tizanidine Hcl | 40 | $1,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $102 | $142,224116 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $148 | $98,31079 claims |
| Novo NordiskOzempic | $235 | $36,21431 claims |
| AbbVieVraylar | $733 | $29,79422 claims |
| NovartisEntresto | $68 | $17,94721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.
Other family in Chesterfield
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.